Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 6 recruiting now early-phase tilt small index

Relapse: early-phase trial registry

6 of 9 indexed Relapse trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

9 US clinical trials · 6 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Relapse: 9 US clinical trials tracked, 6 recruiting.

Relapse is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is UNC Lineberger Comprehensive Cancer Center, running 5 of these trials.

Enrollment posture brief

Registry condition relapse

OPEN 6 | RECR 67% | LATE 0 | EARLY 9 | RANK #1916 | SPON 5

Volume-matched condition peers

Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)

Relapse (this)67%Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Acute Otitis Media22.2%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near Relapse

Relapse lists 6 open slots (67% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Relapse on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Relapse is recruiting above its size-band peers.

    6 of 9 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Relapse research.

    UNC Lineberger Comprehensive Cancer Center accounts for 5 of 9 trials (55.6%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Relapse trials plan to enrol fewer than 100 people.

    Median target enrolment is 31 among the 9 trials that report a genuine target (sentinel values excluded). 9 of those (100%) plan for fewer than 100 participants.

  4. Relapse research is mostly interventional.

    9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 16Phase 23

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 3

Top Sponsors

UNC Lineberger Comprehensive Cancer Center 5 trials
Andrew Yee, MD 1 trials
University of Michigan Rogel Cancer Center 1 trials
Baylor College of Medicine 1 trials
University of Miami 1 trials

Named interventions

Most-linked intervention names on Relapse records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Carfilzomib Drug
2 trials
Pomalidomide Drug
2 trials
Dexamethasone Drug
2 trials
TGFbeta resistant LMP-specific CTLs Biological
1 trials
iC9-CAR.B7-H3 T Cell Therapy Biological
1 trials
iC9-CAR.B7-H3 T cell infusion Biological
1 trials
Cell infusion Biological
1 trials
cyclophosphamide Drug
1 trials

US sites by state

Facility locations filed on Relapse trials. A trial with sites in several states counts in each.

North Carolina 5 trials
Texas 1 trials
Michigan 1 trials
Massachusetts 1 trials
Florida 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Relapse page

9 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Relapse condition card totals 9 registered trials; most-linked intervention Carfilzomib; top US site state North Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.